JNJ-38877605

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：JNJ-38877605	Purity：98% min
CAS NO：943540-75-8	Solubility：DMSO : ≥ 30 mg/mL (79.50 mM)
Molecular Formula：C₁₉H₁₃F₂N₇	Package：Package according to customer requirements
Molecular Weight：377.350	Storage：Store at -20℃

Quality control

Remarks

JNJ-38877605 is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met (mesenchymal-epithelial transition), a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).

Related Products:

MGCD-265 analog; BMS777607; Tivantinib; AMG-208; AMG-458; NVP-BVU972; Golvatinib; SU11274; BMS-794833; PF-04217903; Crizotinib

References

[1]. Perera T, et al. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abst

[2]. De Bacco F, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011 Apr, 103(8), 645-661.

[3]. Torti D, et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer. 2012, 130(6), 1357-1366.